** Amplia Therapeutics ATX.AX slips as much as 14% to A$0.245, lowest since July 4
** Stock marks biggest intraday pct drop since June 30
** Drug developer announces capital raise of A$27.5 mln ($18 mln) at issue price of A$0.23, representing 19.3% discount to last close
** Says funds will support ACCENT and AMPLICITY trials, support ovarian cancer trials of co's lead drug, narmafotinib (AMP945
** Stock last down 10.5%, trims YTD gains to ~192%
($1 = A$1.5253)
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。